Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 154

1.

Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial.

Safaeian M, Sampson JN, Pan Y, Porras C, Kemp TJ, Herrero R, Quint W, van Doorn LJ, Schussler J, Lowy DR, Schiller J, Schiffman MT, Rodriguez AC, Gail MH, Hildesheim A, Gonzalez P, Pinto LA, Kreimer AR; Costa Rica HPV Vaccine Trial (CVT) Group.

J Natl Cancer Inst. 2018 Feb 1;110(2). doi: 10.1093/jnci/djx158.

PMID:
28954299
2.

Correction for Geraets et al., Clinical Evaluation of a GP5+/6+-Based Luminex Assay Having Full High-Risk Human Papillomavirus Genotyping Capability and an Internal Control.

Geraets DT, Cuschieri K, de Koning MN, van Doorn LJ, Snijders PJ, Meijer CJ, Quint WG, Arbyn M.

J Clin Microbiol. 2016 Jul;54(7):1927. doi: 10.1128/JCM.00753-16. No abstract available.

3.

Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods.

Castro FA, Koshiol J, Quint W, Wheeler CM, Gillison ML, Vaughan LM, Kleter B, van Doorn LJ, Chaturvedi AK, Hildesheim A, Schiffman M, Wang SS, Zuna RE, Walker JL, Dunn ST, Wentzensen N.

BMC Infect Dis. 2015 Nov 25;15:544. doi: 10.1186/s12879-015-1281-5.

4.

Gastroenteritis attributable to rotavirus in hospitalized Saudi Arabian children in the period 2007-2008.

Khalil M, Azhar E, Kao M, Al-Kaiedi N, Alhani H, Al Olayan I, Pawinski R, Gopala K, Kandeil W, Anis S, Van Doorn LJ, DeAntonio R.

Clin Epidemiol. 2015 Feb 11;7:129-37. doi: 10.2147/CLEP.S69502. eCollection 2015.

5.

The original SPF10 LiPA25 algorithm is more sensitive and suitable for epidemiologic HPV research than the SPF10 INNO-LiPA Extra.

Geraets DT, Struijk L, Kleter B, Molijn A, van Doorn LJ, Quint WG, Colau B.

J Virol Methods. 2015 Apr;215-216:22-9. doi: 10.1016/j.jviromet.2015.01.001. Epub 2015 Feb 16.

PMID:
25698462
6.

Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA.

Struyf F, Colau B, Wheeler CM, Naud P, Garland S, Quint W, Chow SN, Salmerón J, Lehtinen M, Del Rosario-Raymundo MR, Paavonen J, Teixeira JC, Germar MJ, Peters K, Skinner SR, Limson G, Castellsagué X, Poppe WA, Ramjattan B, Klein TD, Schwarz TF, Chatterjee A, Tjalma WA, Diaz-Mitoma F, Lewis DJ, Harper DM, Molijn A, van Doorn LJ, David MP, Dubin G; HPV PATRICIA Study Group.

Clin Vaccine Immunol. 2015 Feb;22(2):235-44. doi: 10.1128/CVI.00457-14. Epub 2014 Dec 24.

7.

Burden and genotyping of rotavirus disease in the United Arab Emirates: a multicenter hospital-based surveillance.

Howidi M, Balhaj G, Yaseen H, Gopala K, Van Doorn LJ, DeAntonio R.

Hum Vaccin Immunother. 2014;10(8):2284-9. doi: 10.4161/hv.29386.

8.

In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.

Ottosen S, Parsley TB, Yang L, Zeh K, van Doorn LJ, van der Veer E, Raney AK, Hodges MR, Patick AK.

Antimicrob Agents Chemother. 2015 Jan;59(1):599-608. doi: 10.1128/AAC.04220-14. Epub 2014 Nov 10.

9.

Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.

Geraets DT, Cuschieri K, de Koning MN, van Doorn LJ, Snijders PJ, Meijer CJ, Quint WG, Arbyn M.

J Clin Microbiol. 2014 Nov;52(11):3996-4002. doi: 10.1128/JCM.01962-14. Epub 2014 Sep 10. Erratum in: J Clin Microbiol. 2016 Jul;54(7):1927.

10.

Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates.

Lang Kuhs KA, Porras C, Schiller JT, Rodriguez AC, Schiffman M, Gonzalez P, Wacholder S, Ghosh A, Li Y, Lowy DR, Kreimer AR, Poncelet S, Schussler J, Quint W, van Doorn LJ, Sherman ME, Sidawy M, Herrero R, Hildesheim A, Safaeian M; Costa Rica Vaccine Trial Group.

Am J Epidemiol. 2014 Sep 15;180(6):599-607. doi: 10.1093/aje/kwu168. Epub 2014 Aug 19.

11.

Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial.

Lang Kuhs KA, Gonzalez P, Rodriguez AC, van Doorn LJ, Schiffman M, Struijk L, Chen S, Quint W, Lowy DR, Porras C, DelVecchio C, Jimenez S, Safaeian M, Schiller JT, Wacholder S, Herrero R, Hildesheim A, Kreimer AR; Costa Rica Vaccine Trial Group.

J Infect Dis. 2014 Dec 15;210(12):1890-9. doi: 10.1093/infdis/jiu357. Epub 2014 Jun 23.

12.

Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus.

Robbins HA, Li Y, Porras C, Pawlita M, Ghosh A, Rodriguez AC, Schiffman M, Wacholder S, Kemp TJ, Gonzalez P, Schiller J, Lowy D, Esser M, Matys K, Quint W, van Doorn LJ, Herrero R, Pinto LA, Hildesheim A, Waterboer T, Safaeian M.

BMC Infect Dis. 2014 Mar 3;14:120. doi: 10.1186/1471-2334-14-120.

13.

Long-term follow-up of HPV16-positive women: persistence of the same genetic variant and low prevalence of variant co-infections.

Geraets DT, van Doorn LJ, Kleter B, Colau B, Harper DM, Quint WG.

PLoS One. 2013 Nov 11;8(11):e80382. doi: 10.1371/journal.pone.0080382. eCollection 2013.

14.

Racial disparities in Human Papillomavirus (HPV) associated head and neck cancer.

Jiron J, Sethi S, Ali-Fehmi R, Franceschi S, Struijk L, van Doorn LJ, Quint W, Kato I.

Am J Otolaryngol. 2014 Mar-Apr;35(2):147-53. doi: 10.1016/j.amjoto.2013.09.004. Epub 2013 Sep 28.

15.

Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.

Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, Lowy DR, Wacholder S, Schiffman M, Rodriguez AC, Herrero R, Kemp T, Shelton G, Quint W, van Doorn LJ, Hildesheim A, Pinto LA; CVT Group.

Cancer Prev Res (Phila). 2013 Nov;6(11):1242-50. doi: 10.1158/1940-6207.CAPR-13-0203. Erratum in: Cancer Prev Res (Phila). 2016 Jan;9(1):116-7.

16.

Prevalence of and risk factors for oral human papillomavirus among young women in Costa Rica.

Lang Kuhs KA, Gonzalez P, Struijk L, Castro F, Hildesheim A, van Doorn LJ, Rodriguez AC, Schiffman M, Quint W, Lowy DR, Porras C, Delvecchio C, Katki HA, Jimenez S, Safaeian M, Schiller J, Solomon D, Wacholder S, Herrero R, Kreimer AR; Costa Rica Vaccine Trial Group.

J Infect Dis. 2013 Nov 15;208(10):1643-52. doi: 10.1093/infdis/jit369. Epub 2013 Sep 6.

17.

Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica.

Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jimenez S, Schiller JT, Lowy DR, van Doorn LJ, Wacholder S, Kreimer AR; CVT Vaccine Group.

PLoS One. 2013 Jul 17;8(7):e68329. doi: 10.1371/journal.pone.0068329. Print 2013.

18.

Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.

Safaeian M, Kemp TJ, Pan DY, Porras C, Rodriguez AC, Schiffman M, Cortes B, Katki H, Wacholder S, Schiller JT, Gonzalez P, Penrose K, Lowy DR, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Pinto LA.

Hum Vaccin Immunother. 2013 Jul;9(7):1399-406. doi: 10.4161/hv.24340. Epub 2013 Apr 9.

19.

A human papilloma virus testing algorithm comprising a combination of the L1 broad-spectrum SPF10 PCR assay and a novel E6 high-risk multiplex type-specific genotyping PCR assay.

van Alewijk D, Kleter B, Vent M, Delroisse JM, de Koning M, van Doorn LJ, Quint W, Colau B.

J Clin Microbiol. 2013 Apr;51(4):1171-8. doi: 10.1128/JCM.02831-12. Epub 2013 Jan 30.

20.

HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays.

Lin SW, Ghosh A, Porras C, Markt SC, Rodriguez AC, Schiffman M, Wacholder S, Kemp TJ, Pinto LA, Gonzalez P, Wentzensen N, Esser MT, Matys K, Meuree A, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Safaeian M; Costa Rican Vaccine Trial Group.

PLoS One. 2013;8(1):e53067. doi: 10.1371/journal.pone.0053067. Epub 2013 Jan 2.

Supplemental Content

Loading ...
Support Center